상단메뉴 바로가기 본문 바로가기 본문 하위메뉴 바로가기 하단 바로가기

Publications & Patents

HOMEPublications & Patents

Publications & Patents

2022 Front. Microbiol_EC340 endolysin

라이센텍   /   2022-03-11

Combination Effect of Engineered Endolysin EC340 With Antibiotics  

 

Journal 

Front. Microbiol., 15 February 2022

 

https://doi.org/10.3389/fmicb.2022.821936

 

Abstract 

Bacteriophage lysins, also known as endolysins or murein hydrolases, are hydrolytic enzymes produced by bacteriophages during the final stage of the lytic cycle to enable cleavage through the host's cell wall, thus allowing the phages to burst out of their host bacteria after multiplication inside them. When applied externally to Gram-negative bacteria as recombinant proteins, lysins cannot easily reach the cell wall due to the presence of an outer membrane (OM). In this study, endolysin EC340 obtained from phage PBEC131 infecting Escherichia coli was engineered for improved OM permeability and increased activity against Gram-negative bacteria. The engineered endolysin, LNT113, was tested for potential synergistic effects with standard-of-care antibiotics. A synergistic effect was demonstrated with colistin, while an additive effect was seen with meropenem, tigecycline, chloramphenicol, azithromycin, and ciprofloxacin. Neither ceftazidime nor kanamycin showed any synergy or additive effects with the LNT113 endolysin. Moreover, synergy and additive effects could not be generalized by antibiotic class, OM traverse mechanism, molecular weight, or the bactericidal nature of each antibiotic tested.